Biosimilars· September 11, 2026 · 18 min read
Biosimilar Invoice Checks: NDC, HCPCS, Package Size, and Billing Units
By Ran Chen#Biosimilars#HCPCS
Topic
Biosimilars
Follow-on biologics, reference-product erosion, payer switching, launch sequencing, and specialty-channel uptake.
Approvals· August 31, 2026 · 18 min read
Stelara's Pediatric UC License Does Not Write Wezlana Pediatric IBD Substitution
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Pricing & Access· August 18, 2026 · 18 min read
Ziihera's August 25 Gastric Decision: Bispecific vs Trastuzumab Biosimilars
By Ran Chen#Oncology#HER2#Biosimilars
Biosimilars· August 17, 2026 · 18 min read
FDA Biosimilar Device Guidance: Presentations That Are Not Interchangeable
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Pricing & Access· August 13, 2026 · 22 min read
IBD Treatment Access (2026): Stelara & Humira Biosimilars Meet IL-23
Specialty· August 10, 2026 · 16 min read
Rheumatoid Arthritis Treatment Access (2026): Methotrexate, Biosimilars, and JAKs
Biosimilars· August 7, 2026 · 14 min read
Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity
By Ran Chen#Biosimilars#Purple Book#Payer Policy
Pricing & Access· August 3, 2026 · 15 min read
EU Pharmaceutical Procurement by the Numbers (2026): What 35,000 TED Tenders Reveal
By Ran Chen#Market Access#Generic Drugs#Drug Pricing
Pricing & Access· July 27, 2026 · 18 min read
Multiple Sclerosis Disease-Modifying Therapy Access Landscape (2026)
By Ran Chen#Multiple Sclerosis#Biosimilars#Patent Cliff